0216 Woodcock letter
BioCentury & Getty Images


Woodcock defends FDA interactions with drug sponsors

Feb 16, 2021 | 11:48 PM GMT

Acting FDA Commissioner Janet Woodcock has rejected a request to erect a firewall between agency staff who interact with drug companies during the development process and officials who review marketing submissions. Limiting interactions between FDA staff and sponsors would slow drug development and contradict explicit instructions from Congress, Woodcock stated.

The request to prevent review staff from interacting with sponsors was made in a Jan. 28 letter from Michael Carome, director of

Read the full 918 word article

How to gain access

Continue reading with a
two-week free trial.